Strategies to improve stop-smoking support in primary care

Strategies to improve stop-smoking support in primary care

Vanessa Jordan
PEARLS No.
687
Clinical question

How effective are strategies intended to increase the success of smoking cessation interventions in primary care?

Bottom line

This review found moderate‐certainty evidence that adjunctive counselling (delivered by a health professional other than the primary care physician), cost‐free medications and tailored print materials all had a beneficial impact on smoking quit rates. However, a beneficial impact of adjunctive counselling was only evident when offered in addition to standard smoking cessation care.

There was only low‐certainty evidence that biomedical feedback and provider training, and very low‐certainty evidence that provider incentives, had any clear beneficial impact on smoking cessation in this setting.

While there was some evidence of an improvement in some of the markers of physician performance in response to physician training, this did not translate into patient quit attempts.

Caveat

Most of the studies identified in this review were conducted in Europe and the US, and therefore are specific to these settings. As primary care and standard smoking cessation support differ globally, this may affect the applicability of the evidence outside of these settings and may also have contributed to some of the heterogeneity in results.

Context

Primary care is an important setting in which to treat tobacco addiction. However, the rates at which providers address smoking cessation and the success of that support vary. Strategies can be implemented to improve and increase the delivery of smoking cessation support (eg, through provider training) and to increase the amount and breadth of support given to people who smoke (eg, through additional counselling or tailored printed materials).

Cochrane Systematic Review

Lindson N, et al. Strategies to improve smoking cessation rates in primary care. Cochrane Database Syst Rev 2021;9:CD011556. This review contains 81 trials with a total of 112,159 participants.